http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
EC stage 2를 위한 Close-Coupled Catalyst(ccc) System의 개발
김대중(D.J.Kim),최병철(B.C.Choi),손건석(G.S.Son),이귀영(K.Y.Lee),강상록(S.L.Kang) 한국자동차공학회 1995 한국자동차공학회 춘 추계 학술대회 논문집 Vol.1995 No.11_2
A large portion(above 70%) of the engine-out hydrocarbon and NOx emissions for a typical vehicle occur mainly before the conventional underbody catalyst reaches activation temperature. To meet the stringent regulation as EC stage 2, the emissions produced during this period must be reduced. One of alternative techniques is to place CCC(Close-Coupled Catalyst) near the engine manifold. In this study, the characteristics of CCC are observed through ECE+EUDC mode.<br/>
김대중(D.J.Kim),손건석(G.S.Son),이지연(G.Y.Lee),이귀영(K.Y.Lee) 한국자동차공학회 1997 한국자동차공학회 춘 추계 학술대회 논문집 Vol.1997 No.11_1
catalysts were aged in supply gas with or without water vapor according to IAE aging mode. Characteristics of aged catalysts were evaluated using TPR, XRD and XPS. The analysis of XRD and XPS was conducted using curve fitting. The presence of water vapor in supply gas during catalyst aging affected the behavior of surface and bulk reduction(TPR), the structure and particle size(XRD), chemical state and content of Ce³^+ and Rh³^+(XPS).<br/>
신기능장애 및 혈액투석환자에서의 Pyrazinamide 의 약력학적 연구
김대중(D . J . Kim),김성권(S . K . Kim),이정상(J . S . Lee),한용철(Y . C . Han),이문호(M . H . Lee),이선희(S . H . Lee),신상구(S . G . Shin),박찬웅(C . W . Park) 대한내과학회 1986 대한내과학회지 Vol.31 No.1
The pharmacokinetics of single oral dose(lgm) of pyrazinamide was studied in 20 patients with various degrees of renal insufficiency including 6 patients on long-term hemodialysis. The average 24 hr urinary recovery of pyrazinamide in patients with creatinine clearance 10 to 30 ml/hr/kg, and patients with creatinine clearance lesser than 10 ml/hr/kg were 7.5 and 0.9% of administered dose respectively. Serum half-life of the drug was slightly, but significantly(p<0.05), prolonged in patients with creatinine clearance lesser than 10 ml/hr/kg(half-life; 11.25±2.55 hr) compared with normal subjects(half-life; 8.21±1.38 hr) previously reported. The mean serm half-life of pyrazinamide in patients on longterm hemodialysis was 12.26±2.92 hr. The half-life fell to 3.52±1.17 hr during hemodialysis. It was estimated that approximately 41% of drug in the body was removed into dialysate during 4 hr dialysis. The mean dialysance of pyrazinamide was 91.40±2.83 ml/min. From the observed pharmacokinetics of pyrazinamide in patients with impaired renal function, it is suggested that adjustment of dosage regimen may not be required for patients just with impaired renal function. However, replacement of dialysed fraction of pyrazinamide would be required for the maintenance of adequate serum level.